Other substances

5-[(Carbamoylcarbamoyl)amino]-2-methyl-N-[(1R)-1-(naphthalen-1-yl)ethyl]benzamide

A naphtalene derivative.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

5-[(Carbamoylcarbamoyl)amino]-2-methyl-N-[(1R)-1-(naphthalen-1-yl)ethyl]benzamide is an experimental SARS-CoV-2 Papain-like protease inhibitor (Osipiuk et al., 2021).

5-[(Carbamoylcarbamoyl)amino]-2-methyl-N-[(1R)-1-(naphthalen-1-yl)ethyl]benzamide on PubChem

Synonyms

Y95; 5-carbamylurea-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide

 

Structure image - 5-[(Carbamoylcarbamoyl)amino]-2-methyl-N-[(1R)-1-(naphthalen-1-yl)ethyl]benzamide

CC1=C(C=C(C=C1)NC(=O)NC(=O)N)C(=O)N[C@H](C)C2=CC=CC3=CC=CC=C32

Supporting references

Link Tested on Impact factor Notes Publication date
Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
PapainLpro Small molecule Enzyme assay In vitro 		in vitro enzyme assay; Vero E6 cells; SARS-CoV-2 astrain nCoV/Washington/1/2020 12.12

Inhibits SARS-CoV-2 Papain-like protease in vitro with IC50 of ca. 5.1 μM.

 Feb/02/2021
Export (.csv)